Shanghai Duyiwei Biotech Strikes mAb Deal With Apexigen

Published: Mar 06, 2012

March 6, 2012 -- Shanghai Duyiwei Biotechnology, a subsidiary of Gansu Duyiwei Biological Pharma, announced an agreement with California-based Apexigen to develop monoclonal antibody drugs to treat cancer. Shanghai Duyiwei is paying $13.8 million to help underwrite Apexigen’s drug development costs. Apexigen previously established collaborations with Simcere Pharma and 3SBio. More details....

Stock Symbols: (SHE: 002219) (NYSE: SCR) (NSDQ: SSRX)

Back to news